Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL DOPAMINE AGONIST DRUGS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL DOPAMINE AGONIST DRUGS MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 SALES VOLUME DATA
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL DOPAMINE AGONIST DRUGS MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
6 INDUSTRY INSIGHTS
7 EPIDEMIOLOGY
8 REGULATORY FRAMEWORK: GLOBAL DOPAMINE AGONIST DRUGS MARKET
9 PIPELINE ANALYSIS
9.1 PHASE III CANDIDATES
9.2 PHASE II CANDIDATES
9.3 PHASE I CANDIDATES
9.4 OTHERS (PRE-CLINICAL AND RESEARCH)
10 IMPACT OF COVID-19 PANDEMIC ON GLOBAL DOPAMINE AGONIST DRUGS MARKET
10.1 ANALYSIS ON IMPACT OF COVID-19 ON THE MARKET
10.2 AFTERMATH OF COVID-19 AND GOVERNMENT INITIATIVE TO BOOST THE MARKET
10.3 STRATEGIC DECISIONS FOR MANUFACTUERS AFTER COVID-19 TO GAIN COMPETITIVE MARKET SHARE
10.4 PRICE IMPACT
10.5 IMPACT ON DEMAND
10.6 IMPACT ON SUPPLY CHAIN
10.7 CONCLUSION
11 GLOBAL DOPAMINE AGONIST DRUGS MARKET, BY TYPE
11.1 OVERVIEW
11.2 D-1 LIKE DOPAMINE RECEPTORS
11.2.1 D1 RECEPTOR SUBTYPE
11.2.2 D5 RECEPTOR SUBTYPE
11.3 D-2 LIKE DOPAMINE RECEPTORS
11.3.1 D2 RECEPTOR SUBTYPE
11.3.2 D3 RECEPTOR SUBTYPE
11.3.3 D4 RECEPTOR SUBTYPE
12 GLOBAL DOPAMINE AGONIST DRUGS MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 ERGOLINE
12.2.1 BROMOCRIPTINE
12.2.2 CABERGOLINE
12.2.3 LISURIDE
12.2.4 PERGOLIDE
12.2.5 DIHYDROERGOCRYPTINE
12.2.6 OTHERS
12.3 NON-ERGOLINE
12.3.1 CARBIDOPA & LEVODOPA
12.3.2 ROPINIROLE
12.3.3 PRAMIPIXOLE
12.3.4 ROTIGOTINE
12.3.5 APOMORPHINE
12.3.6 PIRIBEDIL
12.3.7 FENOLDOPAM
12.3.8 OTHERS
12.4 OTHERS
13 GLOBAL DOPAMINE AGONIST DRUGS MARKET, BY INDICATION
13.1 OVERVIEW
13.2 PARKINSON’S DISEASE
13.2.1 FAMILIAL PARKINSON’S
13.2.2 EARLY-ONSET PARKINSON’S
13.2.3 SECONDARY PARKINSONISM
13.2.3.1. DEMENTIA WITH LEWY BODIES
13.2.3.2. COTICOABASAL DEGENERATION
13.2.3.3. PROGRESSIVE SUPRANUCLEAR PALSY
13.2.3.4. MULTIPLE SYSTEM ATROPHY
13.3 RESTLESS LEG SYNDROME
13.3.1 MOVEMENT DISORDERS
13.3.2 SLEEP DISORDERS
13.3.3 HYPERKINETIC DISORDERS
13.4 DEPRESSION
13.5 DIABETES
13.6 NEUROLEPTIC MALIGNANT SYNDROME
13.7 HYPERPROLACTINEMIA
13.8 HYPERTENSION
13.9 SCHIZOPHRENIA
13.1 OTHERS
14 GLOBAL DOPAMINE AGONIST DRUGS MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 LIQUID
14.2.2 CAPSULES
14.2.3 TABLETS
14.3 INJECTABLE
14.3.1 SUBCUTANEOUS (UNDER THE SKIN)
14.3.2 INTRAMUSCULAR (IN A MUSCLE)
14.3.3 INTRAVENOUS (IN A VEIN)
15 GLOBAL DOPAMINE AGONIST DRUGS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITAL
15.3 HOMECARE
15.4 SPECIALTY CLINICS
15.5 OTHERS
16 GLOBAL DOPAMINE AGONIST DRUGS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 PHARMACIES
16.2.1 HOSPITAL
16.2.2 RETAIL
16.2.3 OTHERS
16.3 ONLINE STORES
16.4 OTHERS
17 GLOBAL DOPAMINE AGONIST DRUGS MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL DOPAMINE AGONIST DRUGS MARKET, BY REGION
GLOBAL DOPAMINE AGONIST DRUGS MARKET, (GLOBAL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
18.1 NORTH AMERICA
18.1.1 U.S.
18.1.2 CANADA
18.1.3 MEXICO
18.2 EUROPE
18.2.1 GERMANY
18.2.2 FRANCE
18.2.3 U.K.
18.2.4 ITALY
18.2.5 SPAIN
18.2.6 RUSSIA
18.2.7 TURKEY
18.2.8 BELGIUM
18.2.9 HUNGARY
18.2.10 NETHERLANDS
18.2.11 SWITZERLAND
18.2.12 LITHUANIA
18.2.13 AUSTRIA
18.2.14 IRELAND
18.2.15 NORWAY
18.2.16 POLAND
18.2.17 REST OF EUROPE
18.3 ASIA-PACIFIC
18.3.1 JAPAN
18.3.2 CHINA
18.3.3 SOUTH KOREA
18.3.4 INDIA
18.3.5 AUSTRALIA
18.3.6 SINGAPORE
18.3.7 THAILAND
18.3.8 MALAYSIA
18.3.9 INDONESIA
18.3.10 PHILIPPINES
18.3.11 VIETNAM
18.3.12 REST OF ASIA-PACIFIC
18.4 SOUTH AMERICA
18.4.1 BRAZIL
18.4.2 ARGENTINA
18.4.3 PERU
18.4.4 REST OF SOUTH AMERICA
18.5 MIDDLE EAST AND AFRICA
18.5.1 SOUTH AFRICA
18.5.2 SAUDI ARABIA
18.5.3 UAE
18.5.4 EGYPT
18.5.5 ISRAEL
18.5.6 KUWAIT
18.5.7 REST OF MIDDLE EAST AND AFRICA
18.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
19 GLOBAL DOPAMINE AGONIST DRUGS MARKET, SWOT ANALYSIS
20 GLOBAL DOPAMINE AGONIST DRUGS MARKET, COMPANY PROFILE
20.1 GLAXOSMITHKLINE
20.1.1 COMPANY OVERVIEW
20.1.2 REVENUE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT UPDATES
20.2 INTAS PHARMACEUTICALS LTD
20.2.1 COMPANY OVERVIEW
20.2.2 REVENUE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT UPDATES
20.3 AMARIN PHARMACEUTICLAS
20.3.1 COMPANY OVERVIEW
20.3.2 REVENUE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT UPDATES
20.4 ACORDA THERAPEUTICS INC
20.4.1 COMPANY OVERVIEW
20.4.2 REVENUE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT UPDATES
20.5 US WORLDMEDS
20.5.1 COMPANY OVERVIEW
20.5.2 REVENUE ANALYSIS
20.5.3 GEOGRAPHIC PRESENCE
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT UPDATES
20.6 KIRIN HOLDINGS COMPANY LTD
20.6.1 COMPANY OVERVIEW
20.6.2 REVENUE ANALYSIS
20.6.3 GEOGRAPHIC PRESENCE
20.6.4 PRODUCT PORTFOLIO
20.6.5 RECENT UPDATES
20.7 UCB
20.7.1 COMPANY OVERVIEW
20.7.2 REVENUE ANALYSIS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT UPDATES
20.8 BAUSCH HEALTH COMPANIES INC
20.8.1 COMPANY OVERVIEW
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT UPDATES
20.9 BOEHRINGER INGELHEIMCOMPANY OVERVIEW
20.9.1 REVENUE ANALYSIS
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT UPDATES
20.1 INTEC PHARMA
20.10.1 COMPANY OVERVIEW
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT UPDATES
20.11 MERCK
20.11.1 COMPANY OVERVIEW
20.11.2 REVENUE ANALYSIS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT UPDATES
20.12 NOVARTIS AG
20.12.1 COMPANY OVERVIEW
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT UPDATES
20.13 SERINA THERAPEUTICS
20.13.1 COMPANY OVERVIEW
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT UPDATES
20.14 APOTEX INC
20.14.1 COMPANY OVERVIEW
20.14.2 REVENUE ANALYSIS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT UPDATES
20.15 TEVA PHARMACEUTICALS INDUSTRIES LTD
20.15.1 COMPANY OVERVIEW
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT UPDATES
20.16 MYLAN NV
20.16.1 COMPANY OVERVIEW
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT UPDATES
20.17 GLENMARK PHARMACEUTICALS
20.17.1 COMPANY OVERVIEW
20.17.2 REVENUE ANALYSIS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT UPDATES
20.18 SUN PHARMACEUTICALS
20.18.1 COMPANY OVERVIEW
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT UPDATES
20.19 DR REDDYS LABORATORIES.
20.19.1 COMPANY OVERVIEW
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT UPDATES
20.2 CIPLA LTD
20.20.1 COMPANY OVERVIEW
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT UPDATES
21 RELATED REPORTS
22 CONCLUSION
23 QUESTIONNAIRE
24 ABOUT DATA BRIDGE MARKET RESEARCH
